
The following presents the detailed calculation of EPS/(LPS):
	Three Months Ended				Six Months Ended
(MILLIONS)	June 28, 2026		June 29, 2025		June 28, 2026		June 29, 2025
EPS/(LPS) Numerator


Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders	$	(256)	$	2,885	$	2,444	$	5,852
Discontinued operations––net of tax	8		25		(5)		25


Net income/(loss) attributable to Pfizer Inc. common shareholders	$	(248)	$	2,910	$	2,440	$	5,877




EPS/(LPS) Denominator
Weighted-average number of common shares outstanding––Basic	5,699		5,685		5,695		5,680
Common-share equivalents(a)	—		21		38		28
Weighted-average number of common shares outstanding––Diluted	5,699		5,706		5,733		5,708
Anti-dilutive common stock equivalents(b)	45		8		11		12

(a)For the three months ended June 28, 2026, due to the net loss attributable to Pfizer Inc. common shareholders, weighted average common-share equivalents of 35 million shares were not included in the computation of diluted LPS because their inclusion would have had an anti-dilutive effect.

(b)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS/(LPS) for those periods because their inclusion would have had an anti-dilutive effect.